AFT Pharmaceuticals (NZX:AFT) — Material Events

NZX:AFT · 2 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed

Significant Score 75–89

AFT Pharmaceuticals Eyes $300M Revenue with Global Expansion and R&D MilestonesMedium

AFT Pharmaceuticals FY26 revenue up 22%, targets $300M in FY27 with global expansion and R&D progress

24 June 2026 ·Investor Presentation ·85

Notable Score 50–74

FDA Grants Tentative Approval for AFT's Scomara with US Launch Delayed Until 2029Medium

FDA Grants Tentative Approval for AFT's Scomara with US Launch Delayed Until 2029

21 July 2026 ·Regulatory Approval Announcement ·70

Not Assessed Low Score, or missing data

No articles in this tier for the last 12 months.

Market Mentions 2 - appeared in market wrap coverage

These are market wrap articles where AFT Pharmaceuticals (NZX:AFT) was mentioned. They reflect broader market coverage, not company-specific announcements.

Healthcare Wrap - Week 30 (20 July -> 24 July) 2026

25 July 2026

Wrap

Healthcare Wrap - Week 26 (22 June -> 26 June) 2026

27 June 2026

Wrap